News
News
The role of MCED tests in cancer detection
In order to increase the probability of successful cancer treatment, it is important to detect the cancer as early as possible. According to the World Health Organization (WHO) and other sources, two different methods can be distinguished for cancer detection. Early...
Why IFIGENEIA Matters: University of Sarajevo
Discover Why IFIGENEIA Matters from the perspective of the University of Sarajevo. In this one-minute video, Amer Ajanović, Emina Huko, Azra Gazibegović-Busuladžić, Adnan Beganović, Medina Dugonjić, and Naida Ustavdić share why participating in the project is...
Particle Therapy Masterclass in Greece – Online Event
A Particle Therapy MasterClass PTMC took place online in Greece on Saturday, March 28, 2026. The event was conducted entirely online, allowing participants to attend remotely. In particular, the morning programme was broadcasted live through the Veria TechLab of the...
Why IFIGENEIA Matters: Jozef Stefan Institute
Discover Why IFIGENEIA Matters from the perspective of Jožef Stefan Institute. In this one-minute video, mag. Robert Blatnik shares why participating in the project is important for the Institute and how it contributes to the project's broader vision. Watch the video...
ESRR 2026: Advances in Radiopharmacy and Radiochemistry
The 22nd European Symposium on Radiopharmacy and Radiochemistry (ESRR 2026) in Bergen, Norway (April 16-19, 2026) reinforced the critical role of radiopharmaceutical chemistry and production technologies in advancing theranostic nuclear medicine. With approximately...
Reflections from the First Year of IFIGENEIA
Progress, collaboration, and growing impact across science and society As the IFIGENEIA Project completes its first year, the project reflects on a dynamic start marked by scientific progress, growing collaboration, and increasing international visibility. Project...
Did you know: Radiofarmaceuticals and the story behind them
Radiofarmaceuticals are a special type of medicine that use radioactive substances to diagnose or treat diseases, especially cancer. But their story begins more than 100 years ago - with a surprising discovery. In 1896, the French scientist Henri Becquerel...
Meet the IFIGENEIA Partner: CERN, Conseil Européen pour la Recherche Nucléaire
Advancing accelerator science and knowledge transfer, CERN brings its world-leading expertise in particle physics and LINAC technologies to the IFIGENEIA project. Physicists and engineers at CERN use the world's largest and most complex scientific instruments to study...
IFIGENEIA @ 12th International Conference on Isotopes – 12ICI (Florence)
The 12th International Conference on Isotopes (ICI), held in Florence, continues a long-standing series of meetings bringing together scientists across disciplines where isotopes and nuclear radiation play a key role in technological and societal progress. Organised...
Meet the IFIGENEIA partner: GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
A pioneer in particle therapy and accelerator science, GSI Helmholtzzentrum für Schwerionenforschung, with a well-established record of scientific excellence, brings valuable expertise to the IFIGENEIA project, supporting capacity building and advancing innovation...
Meet the IFIGENEIA Partner: German Cancer Research Center
Strengthening cutting-edge cancer research and innovation, the German Cancer Research Center (DKFZ) plays a key role in advancing scientific excellence within the IFIGENEIA project. The Deutsches Krebsforschungszentrum (German Cancer Research Center, DKFZ) is...
2nd IFIGENEIA Meeting in Ljubljana
The IFIGENEIA consortium gathered in Ljubljana on 7 and 8 May 2026 to align progress across scientific, technical, business and capacity-building activities. The 2nd IFIGENEIA Annual Meeting took place in Ljubljana, Slovenia, on 7 and 8 May 2026, bringing together the...